TruDOSE

TruDOSE™ Regenerative Technology focuses on personalizing platelet-based therapy rather than relying on a uniform preparation approach for every patient. Developed by founder and CEO Tapley Holland, the technology uses information about an individual’s platelets to guide preparation for provider-administered treatment. The company works with participating clinics and healthcare professionals interested in structured, data-informed approaches to regenerative care.

President Elena Herning leads national business development and partnerships, helping expand the company’s relationships with clinics and providers. TruDOSE offers a participation pathway for qualified healthcare practices, including an inquiry process, orientation, training, and defined preparation standards. Its work centers on individualized platelet preparation and provider-guided care; claims about treatment outcomes should be evaluated against the available clinical evidence.